Back to search
FDAFDA · Food and drugs·Recall number D-0538-2023

C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402

Published April 26, 2023 · Recall initiated: April 13, 2023

Summary

FDA records drug Class II recall D-0538-2023, published April 26, 2023 and initiated April 13, 2023. Recalling firm: Pharmacy Plus, Inc. dba Vital Care Compounder; Status: Ongoing; Reported quantity: 45 vials; Lot: Lot #: 73810, Exp. Date 5/1/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pharmacy Plus, Inc. dba Vital Care Compounder
Distributor
MS only
Lot
Lot #: 73810, Exp. Date 5/1/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402 recalled?

Yes. FDA published recall D-0538-2023 on April 26, 2023. Reported hazard: Lack of assurance of sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone